#USA #Franklin #Wound Care #Gentell #ManukaMed

Gentell Expands Its Global Presence with Acquisition of ManukaMed

In a strategic move to enhance its global portfolio, Gentell, the world’s largest vertically integrated wound care company, has acquired ManukaMed, a prominent manufacturer of honey-based wound dressings headquartered in New Zealand. This acquisition marks a significant step for Gentell as it continues to broaden its range of specialized wound care products that are not only effective but also backed by scientific research.

About Gentell and the Acquisition

Announced on July 14, 2025, by David Navazio, President and CEO of Gentell, this acquisition grants Gentell access to the only honey-based wound care product that is reimbursable by Medicare and various insurance providers in the United States. The distinct formulation of ManukaMed, which features a patented blend of medical-grade honey, showcases superior healing properties. It is notably effective for treating chronic wounds such as venous ulcers and pressure ulcers, thanks to its ability to lower pH levels and enhance wound healing.

With ManukaMed in its arsenal, Gentell is now positioned to operate factories in seven countries, including the United States, Canada, United Kingdom, Brazil, Paraguay, China, and of course, New Zealand. In addition to the factory locations, Gentell will also take over ManukaMed's U.S. headquarters in Franklin, Tennessee, along with its warehouse and distribution center situated in Kansas City, Missouri, facilitating the rebranding of the company as Gentell ManukaMed.

Strategic Implications of the Acquisition

The implications of this acquisition are significant. In a statement, Navazio remarked, “Gentell's acquisition of ManukaMed enhances our product depth while also facilitating our growth on the Australian continent and in Southeast Asia.” This acquisition not only enables Gentell to deepen its product offerings but also positions the company for expansion into key markets.

Moreover, Gentell has a longstanding relationship with Manuka honey-based products. Edward Quilty, Gentell's Vice President of Corporate Development, previously served as CEO of Derma Sciences and has been a long-time advocate for the use of Manuka honey in wound healing. This expertise fortifies Gentell's alignment with products that are proven to be effective in medical contexts.

Recent Growth and Developments

This acquisition is part of an active year of growth for Gentell, which also includes the acquisition of another wound care manufacturer, Casex, located in South America. Furthermore, the company has recently made significant strides by launching Gentell offices in India, expanding its wound care centers within the U.K., and introducing its ReStorell Liquid Protein Supplement line, which supports effective wound healing.

Gentell's commitment to innovative wound care solutions and its use of advanced technologies in the management of wound care products are evident. Through its manufacturing plants distributed worldwide, the company supplies efficient, affordable, and patient-specific wound care products to various care settings including nursing homes, hospices, and home care facilities.

In addition, Gentell is pioneering the development of advanced wound care databases and logistics systems, aimed at improving the efficiency and effectiveness of wound care management.

Conclusion

As Gentell embarks on this new chapter with ManukaMed, it is clear that their mission to strengthen its global footprint in the wound care industry is well underway. By embracing new opportunities and expanding its product line, Gentell not only reinforces its position as a leader in wound care but also continues to innovate within the healthcare sector, improving the healing process for patients around the world. For those interested in learning more about Gentell’s offerings or to schedule an interview, further information can be found on their website.